A Phase 1 Study of PYX-201 in People With Advanced Solid Tumors

Full Title

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

Purpose

Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:

• Head and neck cancer
• Thyroid cancer
• Salivary gland cancer
• Sarcoma chordoma
• Breast cancer

PYX-201 is an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them, with a reduced risk of harming other cells.

By destroying these cells, PYX-201 may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Winston Wong’s office at 646-608-4245.